How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pelvic-inflammatory-disease-with-neisseria-gonorrhea.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-11 · How we verify

Pelvic Inflammatory Disease with Neisseria Gonorrhea — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pelvic Inflammatory Disease with Neisseria Gonorrhea (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pelvic Inflammatory Disease with Neisseria Gonorrhea, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
ALATROFLOXACIN	ALATROFLOXACIN	Pfizer	alatrofloxacin		1997-01-01
Zithromax	azithromycin	Pfizer Inc.	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Ceftriaxon	Ceftriaxon	Centre Hospitalier Universitaire Vaudois		Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 5 drugs in Pelvic Inflammatory Disease with Neisseria Gonorrhea
Assistance Publique - Hôpitaux de Paris · 1 drug in Pelvic Inflammatory Disease with Neisseria Gonorrhea
Centre Hospitalier Universitaire Vaudois · 1 drug in Pelvic Inflammatory Disease with Neisseria Gonorrhea
Generic (originally Roche) · 1 drug in Pelvic Inflammatory Disease with Neisseria Gonorrhea
Pfizer · 1 drug in Pelvic Inflammatory Disease with Neisseria Gonorrhea
Pfizer Inc. · 1 drug in Pelvic Inflammatory Disease with Neisseria Gonorrhea

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pelvic Inflammatory Disease with Neisseria Gonorrhea:

Cite this brief

Drug Landscape (2026). Pelvic Inflammatory Disease with Neisseria Gonorrhea — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pelvic-inflammatory-disease-with-neisseria-gonorrhea. Accessed 2026-06-11.

Pelvic Inflammatory Disease with Neisseria Gonorrhea full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing